MassMutual Private Wealth & Trust FSB Has $6.11 Million Position in Zoetis Inc. (NYSE:ZTS)

MassMutual Private Wealth & Trust FSB decreased its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 5.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 37,522 shares of the company's stock after selling 2,006 shares during the quarter. MassMutual Private Wealth & Trust FSB's holdings in Zoetis were worth $6,113,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of ZTS. Darwin Wealth Management LLC bought a new position in Zoetis during the third quarter worth about $31,000. First Personal Financial Services acquired a new position in Zoetis during the third quarter worth $33,000. Capital Performance Advisors LLP bought a new position in Zoetis in the third quarter valued at $33,000. Dunhill Financial LLC increased its position in shares of Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company's stock valued at $33,000 after acquiring an additional 75 shares during the last quarter. Finally, Quarry LP increased its position in shares of Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company's stock worth $36,000 after purchasing an additional 153 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Price Performance

Shares of ZTS traded down $3.36 during trading hours on Monday, hitting $166.01. 4,656,629 shares of the company were exchanged, compared to its average volume of 2,078,640. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53. The company has a market cap of $74.90 billion, a price-to-earnings ratio of 31.20, a P/E/G ratio of 2.51 and a beta of 0.89. The firm's fifty day moving average is $170.93 and its 200 day moving average is $180.01.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.46 by $0.12. The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business's revenue for the quarter was up 11.6% on a year-over-year basis. During the same period in the prior year, the company posted $1.36 earnings per share. On average, equities analysts anticipate that Zoetis Inc. will post 5.91 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Tuesday, January 21st. This is a boost from Zoetis's previous quarterly dividend of $0.43. This represents a $2.00 annualized dividend and a yield of 1.20%. Zoetis's dividend payout ratio is presently 32.52%.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ZTS. Leerink Partners started coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an "outperform" rating and a $215.00 target price on the stock. Stifel Nicolaus lowered their price target on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating on the stock in a report on Tuesday, January 7th. JPMorgan Chase & Co. raised their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an "overweight" rating in a research report on Friday, October 11th. Leerink Partnrs raised Zoetis to a "strong-buy" rating in a research report on Monday, December 2nd. Finally, UBS Group started coverage on Zoetis in a report on Monday, December 9th. They set a "neutral" rating and a $196.00 price target for the company. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Zoetis presently has an average rating of "Buy" and a consensus target price of $211.89.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.